Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common complication in patients with cancer, who have an estimated 12-to 23-fold increased risk to develop VTE compared to individuals without cancer. 1 Cancer-associated venous thromboembolism (CAT) is expected to become more frequent due to improved cancer survival, which ultimately results in a larger and older cancer population that is longer exposed to CAT-associated risk factors such as use of chemotherapy and immunotherapy. 2 Besides the substantial morbidity and mortality, CAT may also lead to delayed access to or withdrawal of cancer treatments, prolonged or repeated hospitalizations, thwarting optimal cancer management,